Stock Events

Valneva 

€4.01
5
+€0.02+0.45% Today

Statistics

Day High
4.01
Day Low
4
52W High
-
52W Low
-
Volume
11,001
Avg. Volume
-
Mkt Cap
231.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-2.68
-1.47
-0.26
0.95
Expected EPS
0.4645
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AYJ.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Show more...
CEO
Mr. Thomas Lingelbach
Employees
676
Country
US
ISIN
FR0004056851
WKN
000A0MVJZ

Listings